| TEIKOKU SEIYAKU CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110184066 | Ketoprofen Lysine Salt-Containing Aqueous Patch - A ketoprofen-containing aqueous patch is provided in which not only operational efficiency in producing is improved, but also the aqueous patch has excellent storage stability and transdermal absorption of ketoprofen. The ketoprofen lysine salt-containing aqueous patch includes a backing layer and an adhesive (paste) layer laminated thereon. The aqueous patch includes as a main active ingredient a ketoprofen lysine salt completely dissolved in a paste including not glycerin but a polyethylene glycol having an average molecular weight of 1000 or less. In the ketoprofen lysine salt-containing aqueous patch, the polyethylene glycol having an average molecular weight of 1000 or less is one or more polyethylene glycols selected from the group consisting of Polyethylene glycol 200, Polyethylene glycol 400, Polyethylene glycol 600, and Polyethylene glycol 1000. | 07-28-2011 |
| 20110160194 | Anti-Inflammatory Analgesic External Preparation - An external preparation that effectively produces the anti-inflammatory analgesic effect of a non-steroidal anti-inflammatory analgesic agent, and reduces skin irritation on the application site of the preparation and has an excellent effect on pain associated with inflammation such as chronic rheumatoid arthritis, osteoarthritis, and also lumbago is provided. The external preparation includes a non-steroidal anti-inflammatory analgesic agent and oxybuprocaine or a pharmaceutically acceptable salt thereof. The external preparation includes the non-steroidal anti-inflammatory analgesic agent at a content of 0.1 to 10 wt % based on the total weight of the formulation and oxybuprocaine or a pharmaceutically acceptable salt thereof at a content of 0.01 to 60 wt % based on the total weight of the formulation. The external preparation has a dosage form as an external preparation wherein the dosage form is an ointment, a solution, a suspension, an emulsion, a lotion, a cataplasm, a tape, an aerosol, or a powder for external use. | 06-30-2011 |
| 20110124727 | Oxybuprocaine-Containing Analgesic/Antipruritic External Preparation - An analgesic/antipruritic external preparation that includes a local anesthetic, has fewer side effects, and has an excellent therapeutic effect on pain and itching of the skin is provided. The analgesic/antipruritic external preparation includes oxybuprocaine or a pharmaceutically acceptable salt thereof as an active ingredient, and the oxybuprocaine or a pharmaceutically acceptable salt thereof is contained in an amount of 0.1 to 60 wt %, more preferably 1 to 40 wt %, and most preferably 5 to 30 wt %. The analgesic/antipruritic external preparation has a dosage form as an external preparation wherein the dosage form is an ointment, a solution, a suspension, an emulsion, a lotion, a cataplasm, a tape, an aerosol, or a powder for external use. | 05-26-2011 |
| 20110104215 | TRANSDERMALLY ABSORBABLE PREPARATION - Disclosed is a novel transdermally absorbable preparation which enables the efficient, stable and long-term administration of a drug to a living body. More specifically, the transdermally absorbable preparation comprises: a laminate comprising an outer film, a drug-containing layer and a support layer laminated in this order from the side to be contacted with the skin; and a fixing means for fixing the laminate on the skin. In the transdermally absorbable preparation, the outer film is a drug-permeable polymer film that can control the release of the drug into the skin and is provided as a surface of the laminate which is to be contact with the skin. | 05-05-2011 |
| 20110097407 | Butenafine Hydrochloride-Containing Aqueous Patch - Disclosed is a water-based adhesive skin patch which has excellent storage stability, can achieve excellent accumulation of butenafine hydrochloride contained therein on a patched area such as the skin and a nail, and has a high therapeutic effect. Specifically disclosed is a water-based adhesive skin patch containing butenafine hydrochloride, which is characterized by containing butenafine hydrochloride, glycol salicylate and propylene glycol in a water-containing gel ointment. Specifically, butenafine hydrochloride is dissolved in a mixed solution of glycol salicylate and propylene glycol, and the resulting solution is dispersed in a water-containing gel. Particularly, the mixing ratio of glycol salicylate to propylene glycol is 1:2 to 1:30. | 04-28-2011 |
| 20110003893 | AQUEOUS LOXOPROFEN-CONTAINING PATCHES - An aqueous loxoprofen-containing patch is provided, which has good stability and excellent transdermal absorption of loxoprofen. The aqueous patch includes loxoprofen or a salt thereof and triacetin. Specifically, the aqueous patch includes, based on the weight of the adhesive gel base, 0.1 to 5% by weight of loxoprofen or a salt thereof, 0.5 to 5% by weight of triacetin, 1 to 30% by weight of a water-soluble polymer, 0.01 to 5% by weight of a cross-linking agent, 10 to 90% by weight of purified water, and 0 to 20% by weight of an inorganic powder. | 01-06-2011 |
| 20100298788 | Adhesive Patch and Production Method Thereof - An adhesive patch, such as poultice-type patch, is provided, which is suitable for mass production and allows the user to apply it without touching the drug-containing matrix. A production method of such a adhesive patch is also provided. | 11-25-2010 |
| 20100280467 | Adhesive Patch - An adhesive patch is provided that allows the user to apply it in a safe and hygienic manner without touching the drug-containing matrix during the sequence of actions from the removal of the liner to the application of the patch. Specifically, the adhesive patch has a multilayer structure that includes a backing, an adhesive drug-containing matrix that is spread substantially entirely over one surface of the backing, and a liner that adheres to the drug-containing matrix surface. The adhesive patches have the following features: | 11-04-2010 |
| 20090264374 | UTILIZATION OF ANTI-NEUROPATHIC PAIN EFFECT OF D-ALLOSE AND D-PSICOSE - [PROBLEMS] To control neuropathic pain produced by various mechanisms. | 10-22-2009 |
| 20090221947 | Medicated Patch - A medicated patch is provided which is covered with a liner that enables one to remove the liner unconsciously and readily without losing the initial stickiness of the medicated patch. The external medicated patch includes a backing, an aqueous adhesive drug-containing matrix that is spread substantially entirely over one surface of the backing, and a liner that is larger in size than the surface of the drug-containing matrix to which the liner is attached. The liner larger in size than the surface of the drug-containing matrix to which the liner is attached includes an unattached area that extends from the surface of the drug-containing matrix, or an unattached slack portion that projects upward from the surface of the drug-containing matrix at a position on the surface of the drug-containing matrix. | 09-03-2009 |
| 20090202602 | PHARMACEUTICAL COMPOSITION FOR APPLICATION TO NAIL - Since treatment effects of conventional external preparations were not satisfactory, it is aimed to provide a novel external preparation that is excellent in drug permeability to nail, capable of fully exhibiting effects of an antifungal drug, and effective for treatments of diseases such as nail mycosis and nail candidiasis, particularly, treatments for nail tinea. The external preparation of this invention is a pharmaceutical composition for nail characterized by containing an antifungal drug, alkylpyrrolidone or a derivative thereof, and a crosslinking hydrogel. | 08-13-2009 |
